Inhibition of EGFR Tyrosine-kinase in NSCLC Treatment: the Hungarian Experience with Gefitinib in the Context of an Expanded Access Programme
The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced non-small cell lung cancer (NSCLC) was associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib monotherapy as a second- or third-line treatment for...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2005-11, Vol.25 (6C), p.4759-4762 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4762 |
|---|---|
| container_issue | 6C |
| container_start_page | 4759 |
| container_title | Anticancer research |
| container_volume | 25 |
| creator | OSTOROS, Gyula HARISI, Revekka KOVACS, Gabor HORTI, Jozsef GECZI, Lajos SZONDY, Klara OROSZ, Marta FERENCZI, Eniko RUBY, Eva DOME, Balazs |
| description | The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced non-small cell lung cancer (NSCLC) was
associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib
monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC. Data for 50 patients were analyzed.
Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Programme (EAP). The response rate
was 10% (all partial responses), with disease stabilization in 46% of patients. Disease progression was observed in 44% of
patients. The median survival according to the Kaplan-Meier method was 8 months. Median survival of patients with adenocarcinoma
was significantly increased compared with squamous cell carcinoma and, of the patients responding to therapy, 80% had adenocarcinoma.
The 1-year survival rate was 34%. All patients were evaluable for safety; the adverse events seen with gefitinib were generally
mild and only two patients had to be withdrawn from the study due to adverse events. The Hungarian experience suggests gefitinib
therapy is effective and well tolerated. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68872264</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68872264</sourcerecordid><originalsourceid>FETCH-LOGICAL-h270t-d5067f9ca189219a8b412be9cc5fce98290668baa0c262c12ae39ec40b51c0f43</originalsourceid><addsrcrecordid>eNpF0MtOwzAQBdAIgWh5_ALyBnaR_IjjmF0VlYJUAYKyjibupDEkTrFdAR_BP9OKIlazOXOvZg6SMVOapUoKepiMKZc0VZTKUXISwiulea4LcZyMWC5ExpQYJ993rrW1jXZwZGjIdHbzRBZffgjWYfpmHQQk1pH753JekoVHiD26eE1ii-R241bgLTgy_Vyjt-gMkg8bWzLDZhvpbL3b3dFycBE_467il4Nb4pJMjMEQyKMfVh76Hs-Sowa6gOf7eZq83EwX5W06f5jdlZN52nJFY7qUNFeNNsAKzZmGos4Yr1EbIxuDuuB6e2lRA1DDc24YBxQaTUZryQxtMnGaXP3mrv3wvsEQq94Gg10HDodNqPKiUJznO3ixh5u6x2W19rYH_1X9PXALLvcAgoGu8eCMDf9O8UIJLv8bW7tqP6zHKvTQddtYUYHnssrLKlNSix_uFYf-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68872264</pqid></control><display><type>article</type><title>Inhibition of EGFR Tyrosine-kinase in NSCLC Treatment: the Hungarian Experience with Gefitinib in the Context of an Expanded Access Programme</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>OSTOROS, Gyula ; HARISI, Revekka ; KOVACS, Gabor ; HORTI, Jozsef ; GECZI, Lajos ; SZONDY, Klara ; OROSZ, Marta ; FERENCZI, Eniko ; RUBY, Eva ; DOME, Balazs</creator><creatorcontrib>OSTOROS, Gyula ; HARISI, Revekka ; KOVACS, Gabor ; HORTI, Jozsef ; GECZI, Lajos ; SZONDY, Klara ; OROSZ, Marta ; FERENCZI, Eniko ; RUBY, Eva ; DOME, Balazs</creatorcontrib><description>The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced non-small cell lung cancer (NSCLC) was
associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib
monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC. Data for 50 patients were analyzed.
Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Programme (EAP). The response rate
was 10% (all partial responses), with disease stabilization in 46% of patients. Disease progression was observed in 44% of
patients. The median survival according to the Kaplan-Meier method was 8 months. Median survival of patients with adenocarcinoma
was significantly increased compared with squamous cell carcinoma and, of the patients responding to therapy, 80% had adenocarcinoma.
The 1-year survival rate was 34%. All patients were evaluable for safety; the adverse events seen with gefitinib were generally
mild and only two patients had to be withdrawn from the study due to adverse events. The Hungarian experience suggests gefitinib
therapy is effective and well tolerated.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 16334173</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - enzymology ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - enzymology ; Male ; Medical sciences ; Middle Aged ; Pneumology ; Protein Kinase Inhibitors - therapeutic use ; Quinazolines - therapeutic use ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Survival Rate ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Anticancer research, 2005-11, Vol.25 (6C), p.4759-4762</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17287325$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16334173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OSTOROS, Gyula</creatorcontrib><creatorcontrib>HARISI, Revekka</creatorcontrib><creatorcontrib>KOVACS, Gabor</creatorcontrib><creatorcontrib>HORTI, Jozsef</creatorcontrib><creatorcontrib>GECZI, Lajos</creatorcontrib><creatorcontrib>SZONDY, Klara</creatorcontrib><creatorcontrib>OROSZ, Marta</creatorcontrib><creatorcontrib>FERENCZI, Eniko</creatorcontrib><creatorcontrib>RUBY, Eva</creatorcontrib><creatorcontrib>DOME, Balazs</creatorcontrib><title>Inhibition of EGFR Tyrosine-kinase in NSCLC Treatment: the Hungarian Experience with Gefitinib in the Context of an Expanded Access Programme</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced non-small cell lung cancer (NSCLC) was
associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib
monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC. Data for 50 patients were analyzed.
Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Programme (EAP). The response rate
was 10% (all partial responses), with disease stabilization in 46% of patients. Disease progression was observed in 44% of
patients. The median survival according to the Kaplan-Meier method was 8 months. Median survival of patients with adenocarcinoma
was significantly increased compared with squamous cell carcinoma and, of the patients responding to therapy, 80% had adenocarcinoma.
The 1-year survival rate was 34%. All patients were evaluable for safety; the adverse events seen with gefitinib were generally
mild and only two patients had to be withdrawn from the study due to adverse events. The Hungarian experience suggests gefitinib
therapy is effective and well tolerated.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - enzymology</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - enzymology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pneumology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Quinazolines - therapeutic use</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0MtOwzAQBdAIgWh5_ALyBnaR_IjjmF0VlYJUAYKyjibupDEkTrFdAR_BP9OKIlazOXOvZg6SMVOapUoKepiMKZc0VZTKUXISwiulea4LcZyMWC5ExpQYJ993rrW1jXZwZGjIdHbzRBZffgjWYfpmHQQk1pH753JekoVHiD26eE1ii-R241bgLTgy_Vyjt-gMkg8bWzLDZhvpbL3b3dFycBE_467il4Nb4pJMjMEQyKMfVh76Hs-Sowa6gOf7eZq83EwX5W06f5jdlZN52nJFY7qUNFeNNsAKzZmGos4Yr1EbIxuDuuB6e2lRA1DDc24YBxQaTUZryQxtMnGaXP3mrv3wvsEQq94Gg10HDodNqPKiUJznO3ixh5u6x2W19rYH_1X9PXALLvcAgoGu8eCMDf9O8UIJLv8bW7tqP6zHKvTQddtYUYHnssrLKlNSix_uFYf-</recordid><startdate>20051101</startdate><enddate>20051101</enddate><creator>OSTOROS, Gyula</creator><creator>HARISI, Revekka</creator><creator>KOVACS, Gabor</creator><creator>HORTI, Jozsef</creator><creator>GECZI, Lajos</creator><creator>SZONDY, Klara</creator><creator>OROSZ, Marta</creator><creator>FERENCZI, Eniko</creator><creator>RUBY, Eva</creator><creator>DOME, Balazs</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20051101</creationdate><title>Inhibition of EGFR Tyrosine-kinase in NSCLC Treatment: the Hungarian Experience with Gefitinib in the Context of an Expanded Access Programme</title><author>OSTOROS, Gyula ; HARISI, Revekka ; KOVACS, Gabor ; HORTI, Jozsef ; GECZI, Lajos ; SZONDY, Klara ; OROSZ, Marta ; FERENCZI, Eniko ; RUBY, Eva ; DOME, Balazs</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h270t-d5067f9ca189219a8b412be9cc5fce98290668baa0c262c12ae39ec40b51c0f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - enzymology</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - enzymology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pneumology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Quinazolines - therapeutic use</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OSTOROS, Gyula</creatorcontrib><creatorcontrib>HARISI, Revekka</creatorcontrib><creatorcontrib>KOVACS, Gabor</creatorcontrib><creatorcontrib>HORTI, Jozsef</creatorcontrib><creatorcontrib>GECZI, Lajos</creatorcontrib><creatorcontrib>SZONDY, Klara</creatorcontrib><creatorcontrib>OROSZ, Marta</creatorcontrib><creatorcontrib>FERENCZI, Eniko</creatorcontrib><creatorcontrib>RUBY, Eva</creatorcontrib><creatorcontrib>DOME, Balazs</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OSTOROS, Gyula</au><au>HARISI, Revekka</au><au>KOVACS, Gabor</au><au>HORTI, Jozsef</au><au>GECZI, Lajos</au><au>SZONDY, Klara</au><au>OROSZ, Marta</au><au>FERENCZI, Eniko</au><au>RUBY, Eva</au><au>DOME, Balazs</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of EGFR Tyrosine-kinase in NSCLC Treatment: the Hungarian Experience with Gefitinib in the Context of an Expanded Access Programme</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2005-11-01</date><risdate>2005</risdate><volume>25</volume><issue>6C</issue><spage>4759</spage><epage>4762</epage><pages>4759-4762</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced non-small cell lung cancer (NSCLC) was
associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib
monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC. Data for 50 patients were analyzed.
Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Programme (EAP). The response rate
was 10% (all partial responses), with disease stabilization in 46% of patients. Disease progression was observed in 44% of
patients. The median survival according to the Kaplan-Meier method was 8 months. Median survival of patients with adenocarcinoma
was significantly increased compared with squamous cell carcinoma and, of the patients responding to therapy, 80% had adenocarcinoma.
The 1-year survival rate was 34%. All patients were evaluable for safety; the adverse events seen with gefitinib were generally
mild and only two patients had to be withdrawn from the study due to adverse events. The Hungarian experience suggests gefitinib
therapy is effective and well tolerated.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>16334173</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2005-11, Vol.25 (6C), p.4759-4762 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68872264 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Male Medical sciences Middle Aged Pneumology Protein Kinase Inhibitors - therapeutic use Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Survival Rate Tumors Tumors of the respiratory system and mediastinum |
| title | Inhibition of EGFR Tyrosine-kinase in NSCLC Treatment: the Hungarian Experience with Gefitinib in the Context of an Expanded Access Programme |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T00%3A26%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20EGFR%20Tyrosine-kinase%20in%20NSCLC%20Treatment:%20the%20Hungarian%20Experience%20with%20Gefitinib%20in%20the%20Context%20of%20an%20Expanded%20Access%20Programme&rft.jtitle=Anticancer%20research&rft.au=OSTOROS,%20Gyula&rft.date=2005-11-01&rft.volume=25&rft.issue=6C&rft.spage=4759&rft.epage=4762&rft.pages=4759-4762&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E68872264%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68872264&rft_id=info:pmid/16334173&rfr_iscdi=true |